Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cause-specific mortality coding. methods in the collaborative ocular melanoma study coms report no. 14.

C S Moy1, D M Albert, M Diener-West

  • 1Johns Hopkins University, Baltimore, MD, USA.

Controlled Clinical Trials
|June 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular risk factors and cognitive impairment in a stroke-free cohort.

Neurology·2011
Same author

Association of higher diastolic blood pressure levels with cognitive impairment.

Neurology·2009
Same author

The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS Report No. 17.

Archives of ophthalmology (Chicago, Ill. : 1960)·2001
Same author

The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18.

Archives of ophthalmology (Chicago, Ill. : 1960)·2001
Same author

Evidence for the role of sunlight exposure in the etiology of choroidal melanoma.

Archives of ophthalmology (Chicago, Ill. : 1960)·2001
Same author

Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16.

Ophthalmology·2001

Accurate cause of death determination is crucial in clinical trials. A standardized mortality coding protocol for choroidal melanoma showed that death certificates underestimated metastatic disease, highlighting reporting challenges.

Area of Science:

  • Ophthalmology
  • Oncology
  • Clinical Trials

Background:

  • Ascertaining cause of death is vital in clinical trials with mortality outcomes.
  • Standardized methods for coding mortality are needed for accuracy.

Purpose of the Study:

  • To develop and evaluate a standardized mortality coding protocol for choroidal melanoma.
  • To assess the accuracy of cause of death reporting in a clinical trial setting.

Main Methods:

  • A Mortality Coding Committee (MCC) systematically reviewed clinical and pathologic data for deceased patients.
  • A certainty level was assigned based on pathology review.
  • Agreement was assessed between MCC judgments, clinical center reports, and death certificates.

Main Results:

Related Experiment Videos

  • Of 435 reviewed deaths, 62% were classified as metastatic melanoma, 5% as other malignant tumors, and 21% as uncertain malignancy.
  • 9% died with no evidence of malignancy; 3% had undetermined malignancy status.
  • Fair agreement (kappa = 0.34) was found with death certificates, which underestimated metastatic choroidal melanoma deaths.

Conclusions:

  • Standardized mortality coding is essential for accurate cause-specific mortality assessment in choroidal melanoma trials.
  • Death certificates alone are insufficient for precise reporting of metastatic choroidal melanoma deaths.
  • Detailed review identified challenges in reporting cause-specific mortality for this patient group.